• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should FCS Drug Backing Require Action From Sobi (OM:SOBI) Investors?

    Simply Wall St·10/07/2026 10:32:43
    Listen to the news
    • NICE issued final draft guidance in October 2026 recommending Swedish Orphan Biovitrum’s Tryngolza (olezarsen) for adults in England and Wales with genetically confirmed familial chylomicronaemia syndrome when response to diet and conventional triglyceride-lowering therapies has been inadequate.
    • The guidance recognises Phase 3 BALANCE data in which Tryngolza 80 mg produced a placebo-adjusted 43.5% difference in fasting triglycerides and fewer acute pancreatitis events. This development strengthens Sobi’s rare disease portfolio focused on severe lipid disorders.
    • We will now assess how Swedish Orphan Biovitrum's investment narrative could shift given NICE's draft backing for Tryngolza in FCS.

    Scan Swedish Orphan Biovitrum’s move into ultra rare lipids, then weigh it against other potential opportunities in our hand picked list of list of solid balance sheet and fundamentals (206 results).

    Swedish Orphan Biovitrum Investment Narrative Recap

    To own Swedish Orphan Biovitrum, you need to believe in a rare disease portfolio that can support earnings growth despite pricing pressure, regulatory friction and mixed margin history. The Tryngolza decision fits that story but remains a small part of a larger mix that includes haemophilia, immunology and oncology assets already driving SEK 30,622.0m in revenue.

    In the near term, the key swing factor is execution on product rollouts like Altuvoct, Aspaveli and Gamifant while rebuilding net profit margins from 4.5% after a SEK 7.3b one off loss. The biggest risk is still reimbursement delays and competition that could slow uptake just as management is working to translate forecast 25.02% earnings growth into cleaner results.

    The Tryngolza news connects most clearly to Sobi's broader push into specialty and ultra rare conditions, which already includes products such as Altuvoct, Aspaveli, Gamifant and Vonjo. The NICE draft outcome sits alongside those launches as another test of how Swedish Orphan Biovitrum handles payer engagement, pricing scrutiny and post approval evidence generation in tightly defined indications.

    In terms of catalysts, the focus likely stays on Altuvoct adoption in Europe, international expansion of Gamifant and Vonjo and any progress on new indications. Operationally, the Tryngolza endorsement reinforces the rare disease thesis but does not replace the importance of addressing margin compression, handling competition for Aspaveli and managing stocking or reimbursement issues that have already affected Vonjo.

    Swedish Orphan Biovitrum's narrative projects SEK 41.5b revenue and SEK 9.0b earnings by 2029. This is based on an assumption of 12.8% yearly revenue growth and an earnings increase of roughly SEK 8.1b from SEK 921.0m today.

    Uncover why Swedish Orphan Biovitrum's fair value indicates a 16% potential upside to its current price that could narrow quickly.

    OM:SOBI 1-Year Stock Price Chart
    OM:SOBI 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts focus on Tryngolza as a swing factor. Before this NICE news, the bullish camp was already modelling revenue at SEK 46.9b and earnings of SEK 12.3b by 2029 for Swedish Orphan Biovitrum. You can read that as a far more upbeat story, and then decide which scenario feels closer to your own view.

    Explore 2 other Swedish Orphan Biovitrum fair value estimates, including one that suggests potential upside of up to 159% from the current price.

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Swedish Orphan Biovitrum-Sized Ideas?

    Once you have a view on Swedish Orphan Biovitrum, it can help to compare that thesis with other opportunities that fit clear financial filters using the Simply Wall St Screener.

    • For investors who want potential upside but still care about fundamentals, consider a curated set of businesses flagged as 614 high quality undiscovered gems that might not yet be widely followed.
    • If capital preservation is front of mind, filter for companies with steadier profiles using our screen of 228 resilient stocks with low risk scores that may better match a more cautious approach.
    • Income focused investors can scan for payout opportunities by reviewing 166 dividend fortresses that combine higher yield with a focus on resilience.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.